Abstract
Chronic Pruritus is a common symptom in patients with hepatobiliary disorders such as primary biliary cholangitis (PBC), primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy or hereditary pediatric cholestatic disorders and may accompany, although less frequently, almost any other liver disease. Bile salts, progesterone metabolites and endogenous opioids have been controversially discussed as potential pruritogens. For these substances, however, neither a correlation with itch severity nor a causative link could be established. The G protein-coupled receptor for bile salts, TGR5, has been shown to be expressed in dorsal root ganglia and give rise to itch in rodents, albeit upon stimuli with suprapathological concentrations of bile salts. The semisynthetic bile salt obeticholic acid which exerts antipruritic properties in PBC was shown to worsen itch intensity at high dosages. The potent neuronal activator lysophosphatidic acid (LPA) and its forming enzyme, autotaxin (ATX), could recently be identified in serum of patients suffering from cholestatic pruritus. Autotaxin activity correlated with itch intensity and effectiveness of several anti-pruritic therapeutic interventions in cholestatic patients. Thus, the ATX-LPA-axis may represent a key element in the pathogenesis of this agonizing symptom.
Therapeutic options for cholestatic pruritus are limited to a few evidence-based and several experimental medical and interventional therapies. Current guidelines recommend a step-by-step approach using cholestyramine, rifampicin, naltrexone, and sertraline. Still, a considerable part of patients remains unresponsive to these drugs and requires experimental approaches including albumin dialysis, plasmapheresis, phototherapy, or nasobiliary drainage.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- (N)AFLD:
-
(Non-)alcoholic fatty liver disease
- 5-HT:
-
Serotonin
- ATX:
-
Autotaxin
- CAR:
-
Constitutive androstane receptor
- CYP3A4:
-
Cytochrom P450 Monooxygenases, e.g. 3A4
- DCA:
-
Deoxycholic acid
- ENPP:
-
Ectonucleotide pyrophosphatase
- FXR:
-
Farnesoid X receptor
- GPCR:
-
G protein-coupled receptor
- ICP:
-
Intrahepatic cholestasis of pregnancy
- LCA:
-
Lithocholic acid
- LPA:
-
Lysophosphatidic acid
- MARS:
-
Molecular Adsorbent Recirculating System
- (N)ASH:
-
(Non-)alcoholic steatohepatitis
- OCA:
-
Obeticholic acid
- PAR-2:
-
Protease-activated receptor 2
- PBC:
-
Primary biliary cholangitis
- PSC:
-
Primary sclerosing cholangitis
- PXR:
-
Pregnane X receptor
- QoL:
-
Quality of Life
- UDCA:
-
Ursodeoxycholic acid
- UV-B:
-
Ultraviolet light B
References
Abu-Hayyeh S, Ovadia C, Lieu T, et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology. 2016;63:1287–98.
Akiyama T, Carstens MI, Piecha D, et al. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice. Acta Derm Venereol. 2015;95:147–50.
Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013;123:1513–30.
Bachs L, Pares A, Elena M, et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574–6.
Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992;102:2077–80.
Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain. 1988;33:149–60.
Bartholomew TC, Summerfield JA, Billing BH, et al. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. Clin Sci (Lond). 1982;63:65–73.
Batta AK, Salen G, Mirchandani R, et al. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol. 1993;88:691–700.
Bergasa NV. The pruritus of cholestasis. J Hepatol. 2005;43:1078–88.
Bergasa NV. The itch of liver disease. Semin Cutan Med Surg. 2011;30:93–8.
Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med. 1995;123:161–7.
Bergasa NV, Link MJ, Keogh M, et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol. 2001;96:1563–70.
Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:643–55.
Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology. 1998;27:679–84.
Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992;102:544–9.
Bergasa NV, Thomas DA, Vergalla J, et al. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sci. 1993;53:1253–7.
Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:318–28.
Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology. 2006;44:280–1.
Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399–407.
Borgeat A, Wilder-Smith O, Mentha G, et al. Propofol and cholestatic pruritus. Am J Gastroenterol. 1992;87:672–4.
Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2736–41.
Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum. 1999;42:2204–12.
Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565–75.
Carson KL, Tran TT, Cotton P, et al. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol. 1996;91:1022–3.
Cerio R, Murphy GM, Sladen GE, et al. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol. 1987;116:265–7.
Cevikbas F, Steinhoff M, Ikoma A. Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. CNS Neurosci Ther. 2011;17:742–9.
Chia SC, Bergasa NV, Kleiner DE, et al. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci. 1998;43:2177–83.
Cohen LB, Ambinder EP, Wolke AM, et al. Role of plasmapheresis in primary biliary cirrhosis. Gut. 1985;26:291–4.
Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology. 2005;42:1184–93.
Cribier B, Samain F, Vetter D, et al. Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol. 1998;78:355–7.
Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology. 1990;98:1013–6.
Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J. 1963;1:216–9.
Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323–32.
Decock S, Roelandts R, Steenbergen WV, et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol. 2012;57:637–41.
EASL Clinical Practice Guidelines. Management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.
Elias E. Liver transplantation. J R Coll Physicians Lond. 1993;27:224–32.
Elias E, Burra P. Primary biliary cirrhosis: symptomatic treatment. J Gastroenterol Hepatol. 1991;6:570–3.
Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology. 2002;35:1501–6.
Freedman MR, Holzbach RT, Ferguson DR. Pruritus in cholestasis: no direct causative role for bile acid retention. Am J Med. 1981;70:1011–6.
Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2009;15:2049–66.
Ghent CN, Bloomer JR. Itch in liver disease: facts and speculations. Yale J Biol Med. 1979;52:77–82.
Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology. 1977;73:1125–30.
Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488–93.
Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut. 1990;31:96–9.
Glantz A, Reilly SJ, Benthin L, et al. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology. 2008;47:544–51.
Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799–807.
Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis. Lancet. 1980;2:530.
Hashimoto T, Ohata H, Momose K. Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology. 2004;72:51–6.
Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005–13.
Huesmann M, Huesmann T, Osada N, et al. Cholestatic pruritus: a retrospective analysis on clinical characteristics and treatment response. J Dtsch Dermatol Ges = J Ger Soc Dermatol: JDDG. 2013;11:158–68.
James O, Macklon AF, Watson AJ. Primary biliary cirrhosis – a revised clinical spectrum. Lancet. 1981;1:1278–81.
Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid system. JAMA. 1992;268:3359–62.
Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol. 1999;11:623–31.
Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol. 2000;14:33–40.
Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM. 2002;95:547–52.
Kamei J, Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol. 2001;418:141–5.
Kaplan MM, Schmid C, Provenzale D, et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology. 1999;117:1173–80.
Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26:943–8.
Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res. 1992;597:331–8.
Kirby J, Heaton KW, Burton JL. Pruritic effect of bile salts. Br Med J. 1974;4:693–5.
Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology. 2005;129:894–901.
Koulentaki M, Ioannidou D, Stefanidou M, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol. 2006;101:541–6.
Kremer AE, Beuers U, Oude-Elferink RP, et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163–82.
Kremer AE, Feramisco J, Reeh PW, et al. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochim Biophys Acta. 1842;2014:869–92.
Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008–18.
Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89–97.
Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56:1391–400.
Kuiper EM, van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:1334–40.
LaMotte RH, Dong X, Ringkamp M. Sensory neurons and circuits mediating itch. Nat Rev Neurosci. 2014;15:19–31.
LaMotte RH, Shimada SG, Sikand P. Mouse models of acute, chemical itch and pain in humans. Exp Dermatol. 2011;20:778–82.
LeCluyse EL. Pregnane X, receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact. 2001;134:283–9.
Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int: Off J Int Assoc Study Liver. 2014;34:197–203.
Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999;117:918–25.
Lieu T, Jayaweera G, Zhao P, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology. 2014;147:1417–28.
Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997;336:691–5.
Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.
Macia M, Aviles J, Navarro J, et al. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med. 2003;114:62–4.
Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol. 2006;12:1125–8.
Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005;129:476–85.
Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666–74.
McNeil B, Dong X. Peripheral mechanisms of itch. Neurosci Bull. 2012;28:100–10.
McPhedran NT, Henderson RD. Pruritus and Jaundice. Can Med Assoc J. 1965;92:1258–60.
Mells GF, Pells G, Newton JL, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58:273–83.
Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87:685–91.
Moolenaar WH, Perrakis A. Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol. 2011;12:674–9.
Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–82.e1.
Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut. 1972;13:201–6.
Neff GW, O’Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002;97:2117–9.
Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol. 2001;13:1393–4.
Ng VL, Ryckman FC, Porta G, et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2000;30:152–6.
O’Donohue JW, Pereira SP, Ashdown AC, et al. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther. 2005;21:1041–5.
Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol. 1997;27:1022–8.
Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004;99:1105–10.
Pares A, Herrera M, Aviles J, et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010;53:307–12.
Paus R, Schmelz M, Biro T, et al. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest. 2006;116:1174–86.
Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci. 1991;36:216–20.
Poupon RE, Chretien Y, Poupon R, et al. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology. 1993;17:599–604.
Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436–9.
Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147–57.
Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol. 2006;12:3487–95.
Pusl T, Denk GU, Parhofer KG, et al. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol. 2006;45:887–91.
Quist RG, Ton-Nu HT, Lillienau J, et al. Activation of mast cells by bile acids. Gastroenterology. 1991;101:446–56.
Ramachandran P, Shanmugam NP, Sinani SA, et al. Outcome of partial internal biliary diversion for intractable pruritus in children with cholestatic liver disease. Pediatr Surg Int. 2014;30:1045–9.
Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005;41:747–52.
Reich A, Stander S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol. 2009;89:236–44.
Reyes H, Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med. 2000;32:94–106.
Richardson BP. Serotonin and nociception. Ann N Y Acad Sci. 1990;600:511–9.
Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11:55–67.
Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain. 1995;61:33–7.
Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med. 1973;289:674–8.
Spivey JR, Jorgensen RA, Gores GJ, et al. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 1994;89:2028–32.
Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt. 2006;57:801–7.
Stapelbroek JM, van Erpecum KJ, Klomp LW, et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology. 2006;43:51–3.
Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23:6176–80.
Swain MG. Pruritus and lethargy in the primary billary cirrhosis patient. In: Neuberger J, editor. Primary biliary cirrhosis. Eastbourne: West End Studios; 1999. p. 75–81.
Swain MG, Rothman RB, Xu H, et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology. 1992;103:630–5.
Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362:53–61.
Talwalkar JA, Souto E, Jorgensen RA, et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003;1:297–302.
Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102:1528–36. Epub 2007 Mar 31.
Terg R, Coronel E, Sorda J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002;37:717–22.
Thomas DA, Willams GM, Iwata K, et al. Effects of central administration of opioids on facial scratching in monkeys. Brain Res. 1992;1–2:315–7.
Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ. 1988;297:1501–4.
Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002;435:259–64.
Trauner M, Baghdasaryan A, Claudel T, et al. Targeting nuclear bile acid receptors for liver disease. Dig Dis. 2011;29:98–102.
Turner IB, Rawlins MD, Wood P, et al. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther. 1994;8:337–42.
van der Woerd WL, Kokke FT, van der Zee DC, et al. Total biliary diversion as a treatment option for patients with progressive familial intrahepatic cholestasis and Alagille syndrome. J Pediatr Surg. 2015;50:1846–9.
Villamil AG, Bandi JC, Galdame OA, et al. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med. 2005;118:1160–3.
Walt RP, Daneshmend TK, Fellows IW, et al. Effect of stanozolol on itching in primary biliary cirrhosis. Br Med J (Clin Res Ed). 1988;296:607.
Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflamm Res. 1997;46:412–6.
Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16:3742–7. Epub 2005 Oct 26.
Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113:1264–9.
Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368:1625–34.
Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet. 2003;361:690–4.
Zylicz Z, Krajnik M, Sorge AA, et al. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manag. 2003;26:1105–12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag London
About this chapter
Cite this chapter
Pirschel, W., Kremer, A.E. (2016). Hepatobiliary Diseases. In: Misery, L., Ständer, S. (eds) Pruritus. Springer, Cham. https://doi.org/10.1007/978-3-319-33142-3_34
Download citation
DOI: https://doi.org/10.1007/978-3-319-33142-3_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33140-9
Online ISBN: 978-3-319-33142-3
eBook Packages: MedicineMedicine (R0)